Last updated 2026-09-07
- Raised $900M grant led by Direct Relief, Apr 2026
- Raised $500M debt round led by Royalty Pharma, Jan 2026
- Raised $2.3B Public Offering, Jan 2026
Total raised
$70.5B
Last: PIPE 2026-02
Stage
Public
Founded
1901
Headcount
33,316
HQ
Tel Aviv, Israel
Sector
Pharmaceuticals
About
Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company specializing primarily in generic drugs, but also in branded-drugs, active pharmaceutical ingredients (APIs), and, to a lesser extent, contract manufacturing services and an out-licensing platform. Teva focuses on innovative medicine for various therapeutic areas including neuroscience and immunology for non- and rare diseases. The company's portfolio covers a wide range of therapeutic areas, including central nervous system disorders, respiratory conditions, oncology, and more. Teva aims to help patients live longer, healthier lives and is dedicated to addressing patients' needs, now and in the future.
Funding history · 30 rounds · $70.5B total
30 events/rounds · $70.5B Total Funding: $8.2B in Private Equity, $14.3B in Public Equity, $49.1B in Debt
Apr 2026
Grant
$900.0M
★ Direct Relief★ National Association of Free and Charitable Clinics (NAFC)
Apr 2026
★ Direct Relief★ National Association of Free and Charitable Clinics (NAFC)
Mar 2026
Public Offering
$400.0M
Jan 2026
Debt Financing
$500.0M
★ Royalty PharmaPublicJKI Co., Ltd.Public investorsTeva Pharmaceutical Finance Netherlands III B.V.
Jan 2026
Public Offering
$2.3B
May 2025
Debt Financing
$2.3B
★ Public investors★ Teva Pharmaceutical Finance Netherlands II B.V.★ Teva Pharmaceutical Finance Netherlands IV B.V.★ Teva Pharmaceutical Finance Netherlands III B.V.HSBCMUFGMizuhoPublicCitigroupBNP PARIBASJ.P. MorganHSBC Bank plcBofA SecuritiesIMI-Intesa SanpaoloIntesa Sanpaolo S.p.A.PNC Capital Markets LLCJ.P. Morgan Securities plcMerrill Lynch InternationalGoldman Sachs Bank Europe SE
May 2025
★ HSBC★ Public★ BNP PARIBAS★ J.P. Morgan★ BofA Securities★ Public investors★ IMI-Intesa Sanpaolo★ Teva Pharmaceutical Finance Netherlands II B.V.★ Teva Pharmaceutical Finance Netherlands IV B.V.★ Teva Pharmaceutical Finance Netherlands III B.V.MUFGMizuhoCitigroupPNC Capital Markets LLCGoldman Sachs Bank Europe SE
Mar 2024
PIPE
$150.0M
Jan 2024
Public Offering
$10.0B
★ Public
Nov 2023
Debt Financing
$100.0M
★ Royalty Pharma
Mar 2023
Debt Financing
$864.0M
★ Public★ Public investors★ Teva Pharmaceutical Finance Netherlands II B.V.★ Teva Pharmaceutical Finance Netherlands III B.V.
Mar 2023
Debt Financing
$500.0M
Nov 2021
Debt Financing
$1.0B
Nov 2021
Public Offering
$1.6B
★ Public investors★ Teva Pharmaceutical Finance Netherlands II B.V.★ Teva Pharmaceutical Finance Netherlands III B.V.Public
Jan 2018
PIPE
$1.3B
★ JANA Partners★ Public investors★ Berkshire Hathaway★ Fidelity Investments★ Teva Pharmaceutical Finance Netherlands III B.V.Public
Jul 2016
Debt Financing
$3.5B
★ Public★ Public investors★ Teva Pharmaceutical Finance Netherlands III B.V.
Jul 2016
Debt Financing
$2.0B
Jul 2015
Debt Financing
$33.8B
★ Citi★ BNP Paribas★ Mizuho Bank★ Credit Suisse★ Barclays Bank PLC★ Bank of America Merrill Lynch★ HSBC Ventures★ Morgan Stanley Senior Funding, Inc.HSBCRBC Capital MarketsMorgan Stanley Senior FundingSumitomo Mitsui Banking Corporation
Apr 2012
Debt Financing
$1.1B
Mar 2012
Public Offering
Undisclosed
May 2011
D Round
$6.8B
Sep 2007
C Round
Undisclosed
★ Teva★ Teva PharmaceuticalsTeva Pharmaceutical Industries
Feb 2006
Debt Financing
$1.0B
★ Teva Pharmaceutical Finance Co, LLCPublic investors
Feb 2006
Debt Financing
$500.0M
Feb 2005
A Round
Undisclosed
Feb 1987
Public Offering
Undisclosed
★ NASDAQPublic
1982
Public Offering
Undisclosed
Dec 1981
Public Offering
Undisclosed
Jan 1951
Public Offering
Undisclosed
★ Tel Aviv Stock Exchange (TASE)★ Public (Tel-Aviv Stock Exchange)Public
May 1935
Seed
Undisclosed
★ Else Kober★ Günther Friedländer★ loans from German immigrants★ Günther Friedländer family capitalFamily capitalAlfred FeuchtwangerFamily's own capitalloans from other German immigrants
Acquisitions · 27
Aug 2026
BioXcel Therapeutics (neuroscience product)
Undisclosed
Jun 2026
Emalex Biosciences
$700.0M
Oct 2016
Anda
$500.0M
Aug 2016
Actavis Generics
$40.0B
Oct 2015
Rimsa
$2.3B
Oct 2015
Gecko Health Innovations
Undisclosed
Mar 2015
Auspex Pharmaceuticals
$3.5B
Jun 2014
Labrys Biologics
$825.0M
Jan 2014
NuPathe
$144.0M
Jun 2013
MicroDose Therapeutx
$165.0M
Jul 2011
Taiyo Pharmaceutical Industry
$934.0M
May 2011
Cephalon
$6.8B
Mar 2010
Ratiopharm
$5.0B
Dec 2008
Barr Pharmaceuticals
$7.5B
Jul 2008
Bentley Pharmaceuticals (generic operations)
$360.0M
Jan 2006
Ivax Corporation
$7.4B
Jan 2004
Sicor, Inc.
Undisclosed
Jan 2000
Novopharm
Undisclosed
Aug 1999
Copley Pharmaceutical
$220.0M
Jan 1996
Biocraft
Undisclosed
Jan 1995
Biogal Gyógyszergyár Rt.
Undisclosed
Jan 1995
ICI (Italy)
Undisclosed
Jan 1985
Lemmon Pharmacal Company
Undisclosed
Jan 1980
Ikapharm
Undisclosed
Jan 1980
Plantex
Undisclosed
Jan 1976
Assia and Zori
Undisclosed
Date unknown
Orphahell
Undisclosed
Headcount over time
33,316 employees (2026-09) · 1 point
Offices
Tel Aviv, Israel · HQ / main office
Q&A
- What was Teva Pharmaceuticals' most recent funding round?
- Teva Pharmaceuticals completed a PIPE round in February 2026, raising $400,000,000.
- When did Teva Pharmaceuticals last raise debt financing and for how much?
- Teva Pharmaceuticals raised $500,000,000 in debt financing in January 2026, with Royalty Pharma as a lead investor.
- What was the amount of the Public Offering Teva Pharmaceuticals completed in January 2024?
- In January 2024, Teva Pharmaceuticals completed a Public Offering, raising $10,000,000,000.
- Which company did Teva Pharmaceuticals acquire in June 2026?
- In June 2026, Teva Pharmaceuticals acquired Emalex Biosciences for $700,000,000.
- Who is the current President and CEO of Teva Pharmaceuticals?
- Richard Francis is the President and CEO of Teva Pharmaceuticals.
- How many employees does Teva Pharmaceuticals currently have?
- Teva Pharmaceuticals has over 500 employees.
- What was the most recent grant received by Teva Pharmaceuticals?
- In April 2026, Teva Pharmaceuticals received a grant of $900,000,000 from Direct Relief and National Association of Free and Charitable Clinics (NAFC).
- When did Teva Pharmaceuticals last secure a PIPE investment and from whom?
- In March 2024, Teva Pharmaceuticals secured a PIPE investment of $150,000,000 from Abingworth.
Team · 4
Richard Francis
President and CEO
Sol Barer
Chairman
Eli Kalif
CFO
Eric Hughes
Head of R&D
Sectors & technology
Primary sector
Pharmaceuticals
Target customers
Business model
B2BB2C
Highlights
Patents
Tags
respiratorywomen-healthneurologyoncologygeneric-drugsbiological-therapypharmaceuticalspatientsbiopharmaceuticalnanotechnologychronic-patientsdrug-deliverydoctorsmedical-cannabis
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | tevapharm.com |
|---|---|
| linkedin.com/company/5239 | |
| X / Twitter | twitter.com/tevapharm |
| facebook.com/tevapharm | |
| YouTube | youtube.com/channel/UC9mY1-jUvXsEIS5A2_EjpFg |
| Wikipedia | en.wikipedia.org/wiki/Teva_Pharmaceuticals |
| Wikidata | wikidata.org/wiki/Q898750 |
Identifiers & details
| Legal name | Teva Pharmaceutical Industries Ltd. |
|---|---|
| Founded | 1901 |
| Employees (exact) | 33316 |
| Wikidata QID | Q898750 |
Acquisitions & public offerings
| Acquired | Date | Amount |
|---|---|---|
| BioXcel Therapeutics (neuroscience product) | 2026-08 | |
| Emalex Biosciences | 2026-06 | $700.0M |
| Anda | 2016-10 | $500.0M |
| Actavis Generics | 2016-08 | $40.0B |
| Rimsa | 2015-10 | $2.3B |
| Gecko Health Innovations | 2015-10 | |
| Auspex Pharmaceuticals | 2015-03 | $3.5B |
| Labrys Biologics | 2014-06 | $825.0M |
| NuPathe | 2014-01 | $144.0M |
| MicroDose Therapeutx | 2013-06 | $165.0M |
| Taiyo Pharmaceutical Industry | 2011-07 | $934.0M |
| Cephalon | 2011-05 | $6.8B |
| Ratiopharm | 2010-03 | $5.0B |
| Barr Pharmaceuticals | 2008-12 | $7.5B |
| Bentley Pharmaceuticals (generic operations) | 2008-07 | $360.0M |
| Ivax Corporation | 2006-01 | $7.4B |
| Sicor, Inc. | 2004-01 | |
| Novopharm | 2000-01 | |
| Copley Pharmaceutical | 1999-08 | $220.0M |
| Biocraft | 1996-01 | |
| Biogal Gyógyszergyár Rt. | 1995-01 | |
| ICI (Italy) | 1995-01 | |
| Lemmon Pharmacal Company | 1985-01 | |
| Ikapharm | 1980-01 | |
| Plantex | 1980-01 | |
| Assia and Zori | 1976-01 | |
| Orphahell |
Radar intelligence
Patents
| EPO | 1106 |
|---|
App Store
| App | Rating | Ratings |
|---|---|---|
| Teva Pharmaceutical Events | ||
| Teva Meetings |
Web history (Wayback)
| Domain | tevapharm.com |
|---|
Wikidata
| QID | Q898750 |
|---|
Certificate / subdomain footprint
| Subdomains | 200 |
|---|